0
0
The National Stock Exchange of India (NSE) has announced a landmark investment of Rs 380 crore to construct a state-of-the-art multi-speciality hospital block and bone marrow transplant (BMT) centre at the Tata Memorial Centre’s Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) in Kharghar, Navi Mumbai. The 11-storey facility, expected to begin operations by July 2027, will be India’s largest dedicated bone marrow transplant centre, featuring 60 beds and aiming to perform 600 bone marrow transplants annually while providing 1.3 lakh outpatient consultations each year.
Key Developments and Capacity Expansion
Currently, ACTREC operates a modest five-bed BMT centre, performing over 100 bone marrow transplants annually and serving more than 300 patients daily. The new NSE-funded facility will dramatically expand this capacity, allowing more patients access to complex hematologic cancer treatments. This expansion comes at a critical juncture, as thousands of patients in India await timely BMT treatment, often hindered by facility shortages and high costs.
Dr. Pankaj Chaturvedi, ACTREC director, emphasized the transformative impact of the new centre: “Once the 60-bed building is complete, we will be able to perform 600 bone marrow transplants every year,” noting that it will also be the most affordable BMT facility in the country due to substantial subsidies. In comparison, bone marrow transplants at private hospitals in India can cost upwards of Rs 40 lakh, and even public hospital charges often exceed Rs 10 lakh.
Expert Perspectives and Holistic Cancer Care
Dr. Sudeep Gupta, director of Tata Memorial Centre, highlighted the broader healthcare gap this project addresses. ACTREC currently operates as a standalone cancer centre, and the new hospital block will include specialized services catering to cancer patients’ comorbid conditions such as cardiac, pulmonary, neurological, renal, and gastroenterological disorders. This approach ensures comprehensive, holistic care within a single facility, reducing the need for patients to seek multiple hospital visits.
Dr. Navin Khattry, ACTREC deputy director and head of the BMT program, also acknowledged the importance of scaling up bone marrow transplant capabilities in India, stating that increasing transplant volumes through expanded infrastructure is vital for improving patient outcomes in hematological malignancies and other conditions requiring BMT.
Context and Public Health Implications
Bone marrow transplantation is a life-saving treatment primarily for blood cancers like leukemia, lymphoma, and multiple myeloma, as well as certain non-cancerous blood disorders. The complexity and cost of BMT have historically limited access in India, creating significant treatment disparities. NSE’s CSR-funded project represents a pivotal step toward making advanced cancer treatments more accessible, potentially saving thousands of lives by increasing treatment availability and affordability.
The projected 600 transplants per year will substantially reduce the waiting times for BMT candidates. Additionally, accommodating 1.3 lakh outpatient visits annually reflects the facility’s broader commitment to patient-centric care, emphasizing early diagnosis and follow-up management, which are integral to improving cancer survival rates.Limitations and Balanced Viewpoints
While the new facility is a major advancement, challenges remain in addressing the nationwide demand for BMT services, particularly in rural and underserved regions where healthcare infrastructure is limited. Experts also caution that the availability of beds and transplant services alone will not suffice without parallel investments in skilled healthcare professionals, donor registries, and supportive care infrastructure for post-transplant recovery.
Moreover, although subsidized costs at ACTREC will make BMT more affordable, the overall financial burden of cancer treatment extends beyond transplantation, including drugs, supportive care, and long-term follow-up. Broader policy initiatives and funding mechanisms will be necessary to comprehensively address these facets.
Practical Implications for Readers
For patients and families affected by blood cancers, this development promises new hope through improved access to world-class bone marrow transplants at reduced costs. Healthcare professionals can anticipate enhanced referral capacity and multidisciplinary care opportunities. Public health stakeholders may view this project as a model for collaborative funding and resource expansion to bridge critical gaps in cancer care infrastructure across India.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
